Navigation Links
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Date:6/9/2010

DURHAM, N.C., June 9 -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.

"There is a high unmet need for novel migraine treatments that are effective and safe," said James F. White, Ph.D., President and Chief Executive Officer of CoLucid. "Currently available drugs have varying efficacy and side effects that limit their use in patients. Lasmiditan with its exciting new mechanism of action has the potential to address these patient needs."

In the recently completed double blind, randomized, placebo-controlled parallel group dose-ranging study conducted in five European countries, 391 patients treated a single migraine attack with one of four doses of lasmiditan or placebo. The Phase IIb study met its primary endpoint, showing a highly significant correlation between dose and headache relief at two hours. Individual doses showed significant benefit compared to the placebo from as early as 30 minutes after treatment. Lasmiditan also provided significant relief of other migraine symptoms, as measured in the study, including nausea, photophobia and phonophobia.

Dizziness and fatigue were the most common adverse events reported in the study. No clinically significant adverse effects were identified in either the laboratory parameters or electrocardiography (ECGs). Cardiovascular adverse events, including chest symptoms experienced with the current migraine medication group known as triptans, wer
'/>"/>

Contact: Shirley Chow
Shirley.chow@porternovelli.com
212-601-8308
Porter Novelli
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. LaserCard Corporation Announces Expansion of Middle East Project
4. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
5. Balzan Foundation announces 2007 winners
6. The American Society of Plant Biologists announces 2007 awards
7. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
8. NIST announces 56 new awards for innovative technology research and development
9. Titanium Group Announces Contract With Haitong Securities
10. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
11. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DETROIT In order to support the world,s ... chemicals, polymers and more, new and more efficient ... team of researchers, including several from Wayne State ... of a new grant from the National Science ... Guided Design of Multicomponent Materials for Electrocatalytic Cascade ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... published online in Behavioral Brain Research provides ... as a result of chronic alcohol exposure that can ... Clinical assessments and research indicate that individuals with alcohol ... can occur when people are actively drinking, when they ... , "Sleep-wake disturbances can last for months, or ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... Adolescents who diet and develop disordered eating behaviors ... carry these unhealthy practices into young adulthood and beyond, ... researchers and published in the July 2011 issue of ... "The findings from the current study argue for ...
... University of Illinois researchers identified the top pathogens, pests ... in Food Security. Soybean aphid, soybean rust, soybean cyst ... pathogen, red leaf blotch, were featured as some of ... now and in the future. "Enormous potential exists ...
... HOUSTON (June 23, 2011) The remoteness ... to astronaut health care. One solution is ultrasound. ... (NSBRI) have developed tools that expand the use of ... and underserved locations. These tools include techniques that streamline ...
Cached Biology News:Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3New and old threats to soybean production 2Space research gives birth to new ultrasound tools for health care in orbit, on Earth 2Space research gives birth to new ultrasound tools for health care in orbit, on Earth 3Space research gives birth to new ultrasound tools for health care in orbit, on Earth 4
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... used to kill nematodes. Nematodes are microscopic parasitic ... soil, water, and inside other plants and animals. ... high volatility or other properties promoting migration through ... contain more than 1,000 plant-parasitic nematodes. With more ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... SuperPower, University of Houston, Oak Ridge National Laboratory and ... smart grid demonstration project award announced by U.S. Department ... funds will be used to manufacture a transformer for ... nation,s power grid. , "The project is for ...
... SHANGHAI, Dec. 22 /PRNewswire-Asia/ -- Sundia MediTech, a leading,pharmaceutical ... has received 2009 Deloitte Technology Fast 500 Asia Pacific award.,This ... news was,announced at a ceremony on December 10, 2009 at ... The Deloitte Technology Fast 500 Asia Pacific program is now ...
... , www.bioheartinc.com , The Bioheart ... large quantity of stem cells can be obtained from a patient,s ... cheaply. Adipose stem cells are capable of promoting blood vessel ... Lower limb ischemia is pain, often severe enough to be intolerable, ...
Cached Biology Technology:Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 2Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 3Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 2Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 3Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 4Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 5